Depressive Disorder, Treatment-Resistant Clinical Trial
Official title:
Epidemiology of Treatment Resistant Depression in Taiwan
Verified date | March 2016 |
Source | Johnson & Johnson Pte Ltd |
Contact | n/a |
Is FDA regulated | No |
Health authority | Taiwan: National Health Research Institutes |
Study type | Observational |
The purpose of this study is to assess the epidemiology of Treatment Resistant Depression (TRD) in the nationally insured population in Taiwan including incidence, duration of clinical episodes, and prevalence by age and sex.
Status | Completed |
Enrollment | 8356 |
Est. completion date | February 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Participants who have been continuously enrolled in the insurance plan since January 1, 2004 (ignoring breaks of less than 30 days) and have not received an exclusion diagnosis and during the last 4 months of 2004, a) Have not received a diagnosis of depression and b) Have not received a dispensing of an AD medication - Participants with a diagnosis of a depressive disorder including dysthymic disorder (International Classification of Diseases [ICD]-9 codes 296 depression-related, 300.4, 311) and Major Depressive Disorder (ICD-9 296.2, 296.3) will be followed through December 31, 2013 Exclusion Criteria: - Participants who receive following diagnosis will be excluded, a) Mania, b) Schizophrenia (ICD-9 codes 295), c) Bipolar disorder (ICD-9 codes 296 bipolar-related), D) Dementia (ICD-9 codes 290 or 294); Note: Major depressive disorder (MDD) with psychotic behavior (ICD 296.24 for single episode, ICD 296.34 for recurrent episode) is not an exclusion |
Observational Model: Cohort, Time Perspective: Retrospective
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Johnson & Johnson Pte Ltd | Elysia Group |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence Percentage of Participants with Treatment Resistant Depression | The percentage of beneficiaries of Taiwan's health insurance plan who developed treatment resistant depression during 2005 | Approximately 8 Years | No |
Primary | Prevalence Percentage of Participants with Treatment Resistant Depression | Approximately 8 Years | No | |
Primary | Duration of an episode of Depression | Time from onset of depression to cessation of depression visits and medications. | Approximately 8 Years | No |
Secondary | Healthcare costs | Direct healthcare cost associated with depression treatment will be assessed. | Approximately 8 Years | No |
Secondary | Number of Participants With Comorbidities | Approximately 8 Years | No | |
Secondary | Medications used by Participants with Treatment Resistant Depression | Approximately 8 Years | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03851380 -
Improving Brain Stimulation Through Imaging
|
||
Completed |
NCT04977674 -
Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
|
Early Phase 1 | |
Completed |
NCT03207282 -
Treatment Resistant Depression in America Latina
|
||
Completed |
NCT02452892 -
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
|
N/A | |
Active, not recruiting |
NCT04159012 -
NESBID: Neuro-Stimulation of the Brain in Depression
|
N/A | |
Recruiting |
NCT05870501 -
Synaptic Imaging and Network Activity in Treatment Resistant Depression
|
N/A | |
Completed |
NCT04239651 -
rTMS With and Without iCBT For the Treatment of Resistant Depression (TRD)
|
N/A | |
Completed |
NCT02493868 -
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
Completed |
NCT04599855 -
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression
|
Phase 4 | |
Completed |
NCT03283670 -
Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
|
Phase 2 | |
Recruiting |
NCT03004521 -
Lithium Versus Quetiapine in Treatment Resistant Depression
|
Phase 4 | |
Recruiting |
NCT04783103 -
Neuromodulation in the Elderly Depressed: a Brain Imaging Pilot Study
|
N/A | |
Completed |
NCT03434041 -
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
|
Phase 3 | |
Terminated |
NCT03887624 -
Investigate the Clinical Responses of Ethosuximide in Patients With Treatment-Resistant Depression.
|
Early Phase 1 | |
Completed |
NCT02577250 -
Ketamine Infusions for PTSD and Treatment-Resistant Depression
|
Phase 1 | |
Recruiting |
NCT02610712 -
Clinical Trial of the Use of Ketamine in Treatment Resistant Depression
|
Phase 4 | |
Completed |
NCT03051256 -
Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
|
Phase 2 | |
Enrolling by invitation |
NCT05581797 -
Psilocybin-assisted Interpersonal Therapy for Depression
|
N/A | |
Completed |
NCT02782104 -
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
|
Phase 3 | |
Completed |
NCT04216888 -
Biomarkers of Response to Ketamine in Depression: MRI and Blood Assays Before and After Open Label Intranasal Ketamine
|
Phase 2/Phase 3 |